Literature DB >> 24452866

Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.

Srivalli N Telikepalli1, Ozan S Kumru, Cavan Kalonia, Reza Esfandiary, Sangeeta B Joshi, C Russell Middaugh, David B Volkin.   

Abstract

IgG1 mAb solutions were prepared with and without sodium chloride and subjected to different environmental stresses. Formation of aggregates and particles of varying size was monitored by a combination of size-exclusion chromatography, Nanoparticle Tracking Analysis, Micro-flow Imaging (MFI), turbidity, and visual assessments. Stirring and heating induced the highest concentration of particles. In general, the presence of NaCl enhanced this effect. The morphology of the particles formed from mAb samples exposed to different stresses was analyzed from transmission electron microscopy and MFI images. Shaking samples without NaCl generated the most fibrillar particles, whereas stirring created largely spherical particles. The composition of the particles was evaluated for covalent cross-linking by SDS-PAGE, overall secondary structure by FTIR microscopy, and surface apolarity by extrinsic fluorescence spectroscopy. Freeze-thaw and shaking led to particles containing protein with native-like secondary structure. Heating and stirring produced IgG1-containing aggregates and particles with some non-native disulfide cross-links, varying levels of intermolecular beta sheet content, and increased surface hydrophobicity. These results highlight the importance of evaluating protein particle morphology and composition, in addition to particle number and size distributions, to better understand the effect of solution conditions and environmental stresses on the formation of protein particles in mAb solutions.
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  IgG; accelerated stability; formulation; monoclonal antibody; particle sizing; particles; protein; protein aggregation; stability

Mesh:

Substances:

Year:  2014        PMID: 24452866      PMCID: PMC4040128          DOI: 10.1002/jps.23839

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  60 in total

1.  Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor.

Authors:  Eva Y Chi; Sampathkumar Krishnan; Brent S Kendrick; Byeong S Chang; John F Carpenter; Theodore W Randolph
Journal:  Protein Sci       Date:  2003-05       Impact factor: 6.725

Review 2.  Bioequivalence and the immunogenicity of biopharmaceuticals.

Authors:  Huub Schellekens
Journal:  Nat Rev Drug Discov       Date:  2002-06       Impact factor: 84.694

Review 3.  Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation.

Authors:  Zahra Hamrang; Nicholas J W Rattray; Alain Pluen
Journal:  Trends Biotechnol       Date:  2013-06-14       Impact factor: 19.536

4.  Relevant shaking stress conditions for antibody preformulation development.

Authors:  Annette Eppler; Markus Weigandt; Andrea Hanefeld; Heike Bunjes
Journal:  Eur J Pharm Biopharm       Date:  2009-11-14       Impact factor: 5.571

5.  Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques.

Authors:  Cavan Kalonia; Ozan S Kumru; Jae Hyun Kim; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2013-10-09       Impact factor: 3.534

6.  Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.

Authors:  Paolo Arosio; Simonetta Rima; Massimo Morbidelli
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

7.  Protection mechanism of Tween 80 during freeze-thawing of a model protein, LDH.

Authors:  Anna Hillgren; Jan Lindgren; Maggie Aldén
Journal:  Int J Pharm       Date:  2002-04-26       Impact factor: 5.875

8.  Inhibition of agitation-induced aggregation of an IgG-antibody by hydroxypropyl-beta-cyclodextrin.

Authors:  Tim Serno; John F Carpenter; Theodore W Randolph; Gerhard Winter
Journal:  J Pharm Sci       Date:  2010-03       Impact factor: 3.534

9.  Effect of glycine on pH changes and protein stability during freeze-thawing in phosphate buffer systems.

Authors:  Katherine A Pikal-Cleland; Jeffrey L Cleland; Thomas J Anchordoquy; John F Carpenter
Journal:  J Pharm Sci       Date:  2002-09       Impact factor: 3.534

10.  Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice.

Authors:  Vasco Filipe; Wim Jiskoot; Abdul Hafid Basmeleh; Andhyk Halim; Huub Schellekens; Vera Brinks
Journal:  MAbs       Date:  2012-09-05       Impact factor: 5.857

View more
  25 in total

1.  Bilateral Effects of Excipients on Protein Stability: Preferential Interaction Type of Excipient and Surface Aromatic Hydrophobicity of Protein.

Authors:  Lili Wen; Xianxian Zheng; Xinyue Wang; Hairong Lan; Zongning Yin
Journal:  Pharm Res       Date:  2017-04-11       Impact factor: 4.200

Review 2.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

3.  Effect of Aggregation on the Hydrodynamic Properties of Bovine Serum Albumin.

Authors:  Mariya A Pindrus; James L Cole; Japneet Kaur; Steven J Shire; Sandeep Yadav; Devendra S Kalonia
Journal:  Pharm Res       Date:  2017-07-27       Impact factor: 4.200

4.  Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.

Authors:  Srivalli Telikepalli; Heather E Shinogle; Prem S Thapa; Jae Hyun Kim; Meghana Deshpande; Vibha Jawa; C Russell Middaugh; Linda O Narhi; Marisa K Joubert; David B Volkin
Journal:  J Pharm Sci       Date:  2015-03-05       Impact factor: 3.534

Review 5.  Analytical comparability study of recombinant monoclonal antibody therapeutics.

Authors:  Alexandre Ambrogelly; Stephen Gozo; Amit Katiyar; Shara Dellatore; Yune Kune; Ram Bhat; Joanne Sun; Ning Li; Dongdong Wang; Christine Nowak; Alyssa Neill; Gomathinayagam Ponniah; Cory King; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

Review 6.  Forced degradation of recombinant monoclonal antibodies: A practical guide.

Authors:  Christine Nowak; Jason K Cheung; Shara M Dellatore; Amit Katiyar; Ram Bhat; Joanne Sun; Gomathinayagam Ponniah; Alyssa Neill; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2017-08-30       Impact factor: 5.857

7.  Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.

Authors:  Srivalli Telikepalli; Ozan S Kumru; Jae Hyun Kim; Sangeeta B Joshi; Kristin B O'Berry; Angela W Blake-Haskins; Melissa D Perkins; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-12-17       Impact factor: 3.534

8.  Design and Evaluation of the Highly Concentrated Human IgG Formulation Using Cyclodextrin Polypseudorotaxane Hydrogels.

Authors:  Taishi Higashi; Anna Tajima; Naoko Ohshita; Tatsunori Hirotsu; Irhan Ibrahim Abu Hashim; Keiichi Motoyama; Sawako Koyama; Ruriko Iibuchi; Shiuhei Mieda; Kenji Handa; Tomoaki Kimoto; Hidetoshi Arima
Journal:  AAPS PharmSciTech       Date:  2015-03-17       Impact factor: 3.246

Review 9.  Recombinant antibodies aggregation and overcoming strategies in CHO cells.

Authors:  Tingting Xu; Jihong Zhang; Tianyun Wang; Xiaoyin Wang
Journal:  Appl Microbiol Biotechnol       Date:  2022-05-24       Impact factor: 4.813

10.  Characterization of Grinding-Induced Subvisible Particles and Free Radicals in a Freeze-Dried Monoclonal Antibody Formulation.

Authors:  Zhen-Yi Jing; Guo-Li Huo; Min-Fei Sun; Bin-Bin Shen; Wei-Jie Fang
Journal:  Pharm Res       Date:  2022-01-26       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.